Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$RGBP - Discusses Development Of New Oral Drugs/Pills Near Term That Will Possibly Reprogram & Render Malignant Cancer Cells Benign

www.smallcapsolutions.com

Great News From Regen BioPharma, Inc. Today !!

Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6

Company focuses on developing small molecule checkpoint inhibitors and immune suppressants

www.regenbiopharmainc.com

SAN DIEGO, June 2, 2016 /PRNewswire/ --

Regen BioPharma, Inc., (RGBP) and (RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a "checkpoint inhibitor pill." Previously, the Company reported the use of gene silencing of NR2F6 leads to:

a) induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign and b) immune cell activation, including production of IL-18 and IL-2.

What does this mean in "Layman's Terms"?

"We have gathered several well thought out chemical libraries which are most likely to give us new chemical entities that inhibit and/or activate NR2F6. We are optimistic that this program will identify lead compounds in the near term that potentially create a new generation of immune-stimulatory anticancer drugs. The Company believes these oral drugs will on the one hand unleash anticancer immune responses and on the other hand directly reprogram cancers rendering them less malignant," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "This small molecule approach complements our tCellVax program whereby NR2F6-gene expression in autologous immune cells is inhibited using siRNA. We believe that by using two independent approaches towards the same target we will be in a position to accelerate clinical implementation and diversify our product pipeline. If we are also fortunate enough to identify an activator of NR2F6, we will be in a position to begin a program on treating auto-immune disorders such as rheumatoid arthritis, eczema, graft versus host disease and lupus."

NR2F6 Is a Patented Process

NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patents covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696 was granted to Regen and covers means of screening small molecules such as is being done in this program.

From a Patient Perspective

"From a patient perspective, development of a 'checkpoint inhibitor pill' offers numerous potential advantages to currently utilized checkpoint inhibitors in terms of cost, lack of need for injections, and potentially better control of the drug's activities," said David Koos, Ph.D., Chairman and CEO of Regen.

http://finance.yahoo.com/news/regen-biopharma-inc-discusses-major-110000198.html

Recent Events & Advancements

$RGBP/$RGBPP up list to the OTCQB is Approved

Announces ucVax: Universal Donor Cancer Cellular Immunotherapy

Recent Developments in Aplastic Anemia Therapy May Lead to Future Potential Expansion of (HemaXellerate)

Application was filed for Orphan Drug Designation (HemaXellerate)

(dCellVax) (treatment of Breast Cancer)-Regen believes the comments are near end and the FDA will soon clear this New Drug.

(tCellVax) (treatment of various Cancers-Prostate-Kidney-Liver) IND application filed.

We believe Regen (RGBP & RGBPP) are Long Play's with proven Short Term gain potential.

These are exciting times for Regen as the company moves forward to be a major player in the Stem Cell Treatment-Cure sector. They could quite possibly be a very attractive Buy Out Target.

Many other things are occurring at this time, go to www.regenbiopharmainc.com for more research and/or due diligence. We think you will discover this is a diamond in the rough.

Robert E. Kreh

Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

(OTCPK:RGBP)

Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at www.otcmarkets.com. Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to robkreh@smallcapsolutions.com or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.

Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com and/or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to admin@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.